高カリウム血症治療薬の世界市場

高カリウム血症治療薬の世界市場は2030年までに31億米ドルに達する見込み

2023年に9億700万米ドルと推定される高カリウム血症治療薬の世界市場は、分析期間2023-2030年にCAGR 19.2％で成長し、2030年には31億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである慢性高カリウム血症治療薬は、CAGR 19.7％を記録し、分析期間終了までに19億米ドルに達すると予測されます。急性高カリウム血症治療薬分野の成長率は、分析期間のCAGRで18.3％と推定されます。

米国市場は2億3,840万米ドルと推定、中国はCAGR18.0％で成長予測

米国の高カリウム血症治療薬市場は、2023年に2億3,840万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億6,820万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは18.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ17.7%と16.5%と予測されています。欧州では、ドイツがCAGR約14.0%で成長すると予測されています。

世界の高カリウム血症治療薬市場- 主要動向と促進要因のまとめ

カリウム値上昇の管理に高カリウム血症治療薬が不可欠な理由とは？

高カリウム血症治療薬は、腎臓病、心不全、糖尿病などの慢性疾患を持つ患者のカリウム値上昇の管理に重要な役割を果たしています。高カリウム血症は、血液中のカリウム濃度が異常に高い状態と定義され、適切に管理されなければ、心臓不整脈のような生命を脅かす状態につながる可能性があります。高カリウム血症治療薬の最も一般的なクラスには、ポリスチレンスルホン酸ナトリウム（SPS）のようなカリウム結合剤や、パティロマーやシクロケイ酸ジルコニウムナトリウムのような新しい薬が含まれます。これらの薬剤は、消化管内でカリウムを結合させ、血清カリウム値を下げる働きをします。慢性腎臓病（CKD）と心不全の世界の有病率の増加に伴い、効果的な高カリウム血症管理療法に対する需要が著しく高まっています。

高カリウム血症治療薬市場の主要セグメントは？

薬剤クラス別には、カリウム結合薬、ミネラルコルチコイド受容体拮抗薬、利尿薬などがあります。カリウム結合剤は、カリウム濃度を迅速に低下させる効果があるため、最も広く使用されています。投与経路も重要な要素であり、経口および静脈内投与が主な選択肢です。長期管理には経口薬が好まれ、緊急時には静脈内投与が用いられます。流通チャネルには、病院薬局、小売薬局、オンライン薬局などがあり、クリティカルケア環境でこれらの薬剤が頻繁に使用されることから、病院が最大の市場シェアを占めています。北米と欧州が市場を独占しているが、これは腎臓病の有病率が高いことと、高度なヘルスケア・インフラが整備されていることが背景にあります。

どのような技術革新と臨床革新が高カリウム血症治療薬開発を形成しているのか？

高カリウム血症治療における最近の進歩は、治療の安全性、有効性、患者のコンプライアンスを向上させることに重点を置いています。パティロマーやシクロケイ酸ジルコニウムナトリウムのような新しいカリウム結合剤は、旧来の治療法よりも忍容性が良く、胃腸障害などの副作用が少ないなど、大きな利点を有しています。さらに、これらの薬剤は、慢性高カリウム血症、特に食事や薬剤の変更によってカリウム濃度が変動しやすいCKDや心不全患者において、より良好な長期管理を可能にする可能性を示しています。現在進行中の調査では、併存疾患を効果的に管理するためにこれらの薬剤を他の治療法と併用する可能性が検討されており、臨床試験では急性および慢性の高カリウム血症患者を管理するための広範な用途が引き続き調査されています。

高カリウム血症治療薬市場の成長を促進する要因は何か？

高カリウム血症治療薬市場の成長は、慢性腎臓病や心不全の有病率の上昇、高カリウム血症管理に対する意識の高まり、新規カリウム低下薬の発売など、いくつかの要因によって牽引されています。高齢化と糖尿病罹患率の上昇が高カリウム血症患者の増加にさらに寄与しており、効果的な治療オプションの需要を押し上げています。さらに、予防ヘルスケアと高カリウム血症の早期診断に注目が集まっていることから、長期的な薬剤管理が急増しています。製薬企業も、より効果的な新薬を投入するために研究開発に投資しており、これが今後数年間の市場成長を促進すると予想されます。

調査対象企業の例（全34件）

• AdvaCare Pharma
• ANI Pharmaceuticals, Inc.
• Anumana
• Ardelyx, Inc.
• AstraZeneca PLC
• CSL Ltd.
• KBP Biosciences Pte Ltd.
• Sanofi SA
• Steadfast MediShield Pvt. Ltd.
• Zeria Pharmaceutical Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Hyperkalemia Drugs Market to Reach US$3.1 Billion by 2030

The global market for Hyperkalemia Drugs estimated at US$907.0 Million in the year 2023, is expected to reach US$3.1 Billion by 2030, growing at a CAGR of 19.2% over the analysis period 2023-2030. Chronic Hyperkalemia Drugs, one of the segments analyzed in the report, is expected to record a 19.7% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Acute Hyperkalemia Drugs segment is estimated at 18.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$238.4 Million While China is Forecast to Grow at 18.0% CAGR

The Hyperkalemia Drugs market in the U.S. is estimated at US$238.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$468.2 Million by the year 2030 trailing a CAGR of 18.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.7% and 16.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.0% CAGR.

Global Hyperkalemia Drugs Market - Key Trends and Drivers Summarized

Why Are Hyperkalemia Drugs Essential for Managing Elevated Potassium Levels?

Hyperkalemia drugs play a crucial role in managing elevated potassium levels in patients with chronic conditions such as kidney disease, heart failure, and diabetes. Hyperkalemia, defined as abnormally high potassium levels in the blood, can lead to life-threatening conditions like cardiac arrhythmia if not managed properly. The most common classes of hyperkalemia drugs include potassium binders, such as sodium polystyrene sulfonate (SPS), and newer medications like patiromer and sodium zirconium cyclosilicate. These drugs work by binding potassium in the gastrointestinal tract, helping to lower serum potassium levels. With the increasing prevalence of chronic kidney disease (CKD) and heart failure globally, the demand for effective hyperkalemia management therapies has grown significantly.

What Are the Key Segments in the Hyperkalemia Drugs Market?

Drug classes include potassium binders, mineralocorticoid receptor antagonists, and diuretics. Potassium binders are the most widely used due to their effectiveness in rapidly reducing potassium levels. Route of administration is another important factor, with oral and intravenous routes being the primary options. Oral drugs are preferred for long-term management, while intravenous options are used in emergency settings. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, with hospitals holding the largest market share due to the frequent use of these drugs in critical care settings. North America and Europe dominate the market, driven by a high prevalence of kidney diseases and the availability of advanced healthcare infrastructure.

What Technological and Clinical Innovations Are Shaping Hyperkalemia Drug Development?

Recent advancements in hyperkalemia treatment have focused on improving the safety, efficacy, and patient compliance of therapies. Newer potassium binders like patiromer and sodium zirconium cyclosilicate offer significant advantages over older treatments, including better tolerability and fewer side effects, such as gastrointestinal disturbances. Additionally, these drugs have shown promise in enabling better long-term management of chronic hyperkalemia, particularly in patients with CKD or heart failure, where potassium levels can fluctuate due to diet or medication changes. Ongoing research is exploring the potential for combining these drugs with other therapies to manage comorbid conditions effectively, while clinical trials continue to investigate their broader applications in managing acute and chronic hyperkalemia cases.

What Factors Are Driving Growth in the Hyperkalemia Drugs Market?

The growth in the hyperkalemia drugs market is driven by several factors, including the rising prevalence of chronic kidney disease and heart failure, increasing awareness of hyperkalemia management, and the launch of novel potassium-lowering drugs. The aging population and the rising incidence of diabetes are further contributing to the rise in hyperkalemia cases, thereby boosting the demand for effective treatment options. Additionally, the growing focus on preventive healthcare and early diagnosis of hyperkalemia has led to a surge in long-term drug management. Pharmaceutical companies are also investing in research and development to introduce new and more effective drugs, which is expected to drive market growth in the coming years.

Select Competitors (Total 34 Featured) -

• AdvaCare Pharma
• ANI Pharmaceuticals, Inc.
• Anumana
• Ardelyx, Inc.
• AstraZeneca PLC
• CSL Ltd.
• KBP Biosciences Pte Ltd.
• Sanofi SA
• Steadfast MediShield Pvt. Ltd.
• Zeria Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Hyperkalemia Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Chronic Kidney Disease (CKD) and Heart Failure Spurs Demand for Hyperkalemia Drugs
  • Technological Advancements in Drug Delivery Systems Strengthen Business Case for Hyperkalemia Treatments
  • Growing Focus on Early Diagnosis and Preventive Care Expands Addressable Market for Hyperkalemia Medications
  • Increasing Availability of Potassium Binders Accelerates Demand for Oral Hyperkalemia Therapies
  • Surge in Geriatric Population Drives Adoption of Hyperkalemia Drugs for Age-related Disorders
  • Rising Incidence of Hyperkalemia in Diabetic Patients Propels Market Growth
  • Technological Innovations in Potassium-lowering Therapies Enhance Patient Compliance and Treatment Outcomes
  • Increasing FDA Approvals of Novel Hyperkalemia Drugs Expands Market Opportunities
  • Growing Focus on Chronic Hyperkalemia Management Strengthens Business Case for Long-term Treatment Solutions
  • Rising Adoption of Hyperkalemia Medications in Critical Care Settings Spurs Growth
  • Rising Availability of Combination Therapies for Hyperkalemia and Related Disorders Expands Market Scope
  • Increasing Use of Hyperkalemia Drugs in Outpatient Settings Strengthens Business Case for Convenience-driven Solutions
  • Growing Healthcare Expenditure in Emerging Markets Expands Addressable Market for Hyperkalemia Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Hyperkalemia Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Hyperkalemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Hyperkalemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Chronic Hyperkalemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Chronic Hyperkalemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Chronic Hyperkalemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Acute Hyperkalemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Acute Hyperkalemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Acute Hyperkalemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Hyperkalemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 11: USA Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 12: USA Historic Review for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: USA 16-Year Perspective for Hyperkalemia Drugs by Type - Percentage Breakdown of Value Sales for Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 14: Canada Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 15: Canada Historic Review for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: Canada 16-Year Perspective for Hyperkalemia Drugs by Type - Percentage Breakdown of Value Sales for Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs for the Years 2014, 2024 & 2030
• JAPAN
  • Hyperkalemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 17: Japan Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Japan Historic Review for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: Japan 16-Year Perspective for Hyperkalemia Drugs by Type - Percentage Breakdown of Value Sales for Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs for the Years 2014, 2024 & 2030
• CHINA
  • Hyperkalemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 20: China Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: China Historic Review for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: China 16-Year Perspective for Hyperkalemia Drugs by Type - Percentage Breakdown of Value Sales for Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs for the Years 2014, 2024 & 2030
• EUROPE
  • Hyperkalemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 23: Europe Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: Europe Historic Review for Hyperkalemia Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: Europe 16-Year Perspective for Hyperkalemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Hyperkalemia Drugs by Type - Percentage Breakdown of Value Sales for Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs for the Years 2014, 2024 & 2030
• FRANCE
  • Hyperkalemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 29: France Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: France Historic Review for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: France 16-Year Perspective for Hyperkalemia Drugs by Type - Percentage Breakdown of Value Sales for Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs for the Years 2014, 2024 & 2030
• GERMANY
  • Hyperkalemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 32: Germany Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Germany Historic Review for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Germany 16-Year Perspective for Hyperkalemia Drugs by Type - Percentage Breakdown of Value Sales for Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 35: Italy Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Italy Historic Review for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Italy 16-Year Perspective for Hyperkalemia Drugs by Type - Percentage Breakdown of Value Sales for Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Hyperkalemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 38: UK Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: UK Historic Review for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: UK 16-Year Perspective for Hyperkalemia Drugs by Type - Percentage Breakdown of Value Sales for Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Rest of Europe Historic Review for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Rest of Europe 16-Year Perspective for Hyperkalemia Drugs by Type - Percentage Breakdown of Value Sales for Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Hyperkalemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Asia-Pacific Historic Review for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Asia-Pacific 16-Year Perspective for Hyperkalemia Drugs by Type - Percentage Breakdown of Value Sales for Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Rest of World Historic Review for Hyperkalemia Drugs by Type - Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Rest of World 16-Year Perspective for Hyperkalemia Drugs by Type - Percentage Breakdown of Value Sales for Chronic Hyperkalemia Drugs and Acute Hyperkalemia Drugs for the Years 2014, 2024 & 2030

IV. COMPETITION